Abstract
Background: The aim of the study was to assess the screening performance of first trimester maternal serum measurements of A-disintegrin-and-metalloprotease 12-s (ADAM12s) and placental protein 13 (PP13) for preeclampsia (PE), gestational hypertension (GH) and small-for-gestational-age (SGA) fetuses.
Methods: In this retrospective case-control study 220 pregnant women were matched for gestational and maternal age at sampling. Results were expressed as multiples of the median (MoM) and compared using Kruskal-Wallis and Mann-Whitney U-test. Screening performance was assessed by receiver operator characteristics (ROC) curves and area under the curve (AUC).
Results: Seventeen cases of PE, 30 cases of GH and eight cases of SGA fetuses were matched with 165 controls. ROC-analysis yielded AUCs for ADAM12s and PP13 of 0.63 and 0.59 for PE, 0.68 and 0.57 for GH and 0.59 and 0.62 for SGA, respectively. Combined ADAM12 and PP13 did not improve the AUC value. When the specificity was set at 80%, corresponding detection rate of ADAM12s was 52% for GH.
Conclusions: Combined ADAM12s and PP13 measurements do not predict adverse pregnancy outcome, but decreased first trimester ADAM12s levels are associated with GH.
We would like to thank Carla Beertsen, laboratory assistant at the Department of Clinical Chemistry at VU University Medical Center, for her excellent support in laboratory research.
Conflict of interest statement
Authors’ conflict of interest disclosure: The authors stated that there are no conflicts of interest regarding the publication of this article.
Research funding: None declared.
Employment or leadership: None declared.
Honorarium: None declared.
Guarantor: KLD.
Contributorship: KLD, IHL and JMGV conceived the study and wrote the manuscript, MWH performed statistical analysis, MAB and ACH performed serum testing.
References
1. Lyall F. The human placental bed revisited. Placenta 2002;23:555–62.10.1053/plac.2002.0850Search in Google Scholar PubMed
2. Meekins JW, Pijnenborg R, Hanssens M, McFadyen IR, van AA. A study of placental bed spiral arteries and trophoblast invasion in normal and severe pre-eclamptic pregnancies. Br J Obstet Gynaecol 1994;10:669–74.10.1111/j.1471-0528.1994.tb13182.xSearch in Google Scholar PubMed
3. Pijnenborg R, Anthony J, Davey DA, Rees A, Tiltman A, Vercruysse L, et al. Placental bed spiral arteries in the hypertensive disorders of pregnancy. Br J Obstet Gynaecol 1991;98:648–55.10.1111/j.1471-0528.1991.tb13450.xSearch in Google Scholar PubMed
4. Melchiorre K, Leslie K, Prefumo F, Bhide A, Thilaganathan B. First-trimester uterine artery Doppler indices in the prediction of small-for-gestational age pregnancy and intrauterine growth restriction. Ultrasound Obstet Gynecol 2009;33:524–9.http://gateway.webofknowledge.com/gateway/Gateway.cgi?GWVersion=2&SrcApp=PARTNER_APP&SrcAuth=LinksAMR&KeyUT=000266365100006&DestLinkType=FullRecord&DestApp=ALL_WOS&UsrCustomerID=b7bc2757938ac7a7a821505f8243d9f310.1002/uog.6368Search in Google Scholar PubMed
5. Deurloo KL, Spreeuwenberg MD, Bolte AC, van Vugt JM. Color Doppler ultrasound of spiral artery blood flow for prediction of hypertensive disorders and intra uterine growth restriction: a longitudinal study. Prenat Diagn 2007;27:1011–6.10.1002/pd.1822Search in Google Scholar PubMed
6. De Vivo A, Baviera G, Giordano D, Todarello G, Corrado F, D’anna R. Endoglin, Pl GF and sFlt-1 as markers for predicting pre-eclampsia. Acta Obstet Gynecol Scand 2008;87:837–42.10.1080/00016340802253759http://gateway.webofknowledge.com/gateway/Gateway.cgi?GWVersion=2&SrcApp=PARTNER_APP&SrcAuth=LinksAMR&KeyUT=000258450200008&DestLinkType=FullRecord&DestApp=ALL_WOS&UsrCustomerID=b7bc2757938ac7a7a821505f8243d9f3Search in Google Scholar PubMed
7. Smith GC, Crossley JA, Aitken DA, Jenkins N, Lyall F, Cameron AD, et al. Circulating angiogenic factors in early pregnancy and the risk of preeclampsia, intrauterine growth restriction, spontaneous preterm birth, and stillbirth. Obstet Gynecol 2007;109:1316–24.http://gateway.webofknowledge.com/gateway/Gateway.cgi?GWVersion=2&SrcApp=PARTNER_APP&SrcAuth=LinksAMR&KeyUT=000247010200010&DestLinkType=FullRecord&DestApp=ALL_WOS&UsrCustomerID=b7bc2757938ac7a7a821505f8243d9f310.1097/01.AOG.0000265804.09161.0dSearch in Google Scholar PubMed
8. Poon LC, Maiz N, Valencia C, Plasencia W, Nicolaides KH. First-trimester maternal serum pregnancy-associated plasma protein-A and pre-eclampsia. Ultrasound Obstet Gynecol 2009;33:23–33.10.1002/uog.6280Search in Google Scholar PubMed
9. Spencer K, Cowans NJ, Nicolaides KH. Low levels of maternal serum PAPP-A in the first trimester and the risk of pre-eclampsia. Prenat Diagn 2008;28:7–10.10.1002/pd.1890Search in Google Scholar PubMed
10. Gilpin BJ, Loechel F, Mattei MG, Engvall E, Albrechtsen R, Wewer UM. A novel, secreted form of human ADAM 12 (meltrin alpha) provokes myogenesis in vivo. J Biol Chem 1998;273: 157–66.10.1074/jbc.273.1.157Search in Google Scholar PubMed
11. Cowans NJ, Spencer K. First-trimester ADAM12 and PAPP-A as markers for intrauterine fetal growth restriction through their roles in the insulin-like growth factor system. Prenat Diagn 2007;27:264–71.10.1002/pd.1665Search in Google Scholar PubMed
12. Laigaard J, Sorensen T, Placing S, Holck P, Fröhlich C, Wøjdemann KR, et al. Reduction of the disintegrin and metalloprotease ADAM12 in preeclampsia. Obstet Gynecol 2005;106:144–9.10.1097/01.AOG.0000165829.65319.65Search in Google Scholar PubMed
13. Spencer K, Cowans NJ, Stamatopoulou A. ADAM12s in maternal serum as a potential marker of pre-eclampsia. Prenat Diagn 2008;28:212–6.10.1002/pd.1957Search in Google Scholar PubMed
14. Pihl K, Larsen T, Krebs L, Christiansen M. First trimester maternal serum PAPP-A, beta-hCG and ADAM12 in prediction of small-for-gestational-age fetuses. Prenat Diagn 2008;28:1131–5.10.1002/pd.2141Search in Google Scholar PubMed
15. Matwejew E, Cowans NJ, Stamatopoulou A, Spencer K, von Kaisenberg CS. Maternal serum ADAM-12 as a potential marker for different adverse pregnancy outcomes. Fetal Diagn Ther 2010;27:32–9.http://gateway.webofknowledge.com/gateway/Gateway.cgi?GWVersion=2&SrcApp=PARTNER_APP&SrcAuth=LinksAMR&KeyUT=000274051800006&DestLinkType=FullRecord&DestApp=ALL_WOS&UsrCustomerID=b7bc2757938ac7a7a821505f8243d9f310.1159/000275669Search in Google Scholar PubMed
16. Poon LC, Chelemen T, Granvillano O, Pandeva I, Nicolaides KH. First-trimester maternal serum a disintegrin and metalloprotease 12 (ADAM12) and adverse pregnancy outcome. Obstet Gynecol 2008;112:1082–90.10.1097/AOG.0b013e318188d6f9Search in Google Scholar PubMed
17. Linskens IH, Twisk JW, Blankenstein MA, van Vugt JM. First trimester maternal serum ADAM12s levels in twin pregnancies. Prenat Diagn 2010;30:352–6.10.1002/pd.2494Search in Google Scholar PubMed
18. Visegrady B, Than NG, Kilar F, Sumegi B, Than GN, Bohn H. Homology modelling and molecular dynamics studies of human placental tissue protein 13 (galectin-13). Protein Eng 2001;14:875–80.10.1093/protein/14.11.875Search in Google Scholar PubMed
19. Chafetz I, Kuhnreich I, Sammar M, Tal Y, Gibor Y, Meiri H, et al. First-trimester placental protein 13 screening for preeclampsia and intrauterine growth restriction. Am J Obstet Gynecol 2007;197:35–7.10.1016/j.ajog.2007.02.025Search in Google Scholar PubMed
20. Gonen R, Shahar R, Grimpel YI, Chefetz I, Sammar M, Meiri H, et al. Placental protein 13 as an early marker for pre-eclampsia: a prospective longitudinal study. Br J Obstet Gynaecol 2008;115:1465–72.10.1111/j.1471-0528.2008.01902.xSearch in Google Scholar PubMed
21. Nicolaides KH, Bindra R, Turan OM, Chefetz I, Sammar M, Meiri H, et al. A novel approach to first-trimester screening for early pre-eclampsia combining serum PP-13 and Doppler ultrasound. Ultrasound Obstet Gynecol 2006;27:13–7.10.1002/uog.2686Search in Google Scholar PubMed
22. Spencer K, Cowans NJ, Chefetz I, Tal J, Kuhnreich I, Meiri H. Second-trimester uterine artery Doppler pulsatility index and maternal serum PP13 as markers of pre-eclampsia. Prenat Diagn 2007;27:258–63.10.1002/pd.1664Search in Google Scholar PubMed
23. Cowans NJ, Spencer K, Meiri H. First-trimester maternal placental protein 13 levels in pregnancies resulting in adverse outcomes. Prenat Diagn 2008;28:121–5.10.1002/pd.1921Search in Google Scholar PubMed
24. Cowans NJ, Stamatopoulou A, Jaakohuhta S, Spencer K. ADAM-12 stability in first trimester maternal serum. Prenat Diagn 2010;30:555–60.10.1002/pd.2522Search in Google Scholar PubMed
25. Cowans NJ, Stamatopoulou A, Jaakohuhta S, Hentunen S, Spencer K. PP13 stability in first trimester maternal serum and whole blood. Prenat Diagn 2010;30:582–5.10.1002/pd.2538Search in Google Scholar PubMed
26. Linskens IH, Beertsen CM, van Vugt JM, Blankenstein MA, Heijboer AC. Processing effects and storage conditions on A Disintegrin and Metalloprotease (ADAM12s), a maternal serum marker for adverse pregnancy outcome. Clin Chem Lab Med 2009;47:1579–81.http://gateway.webofknowledge.com/gateway/Gateway.cgi?GWVersion=2&SrcApp=PARTNER_APP&SrcAuth=LinksAMR&KeyUT=000272257900022&DestLinkType=FullRecord&DestApp=ALL_WOS&UsrCustomerID=b7bc2757938ac7a7a821505f8243d9f3Search in Google Scholar
27. Brown MA, Lindheimer MD, de Swiet SM, van Assche AA, Moutquin JM. The classification and diagnosis of the hypertensive disorders of pregnancy: statement from the International Society for the Study of Hypertension in Pregnancy (ISSHP). Hypertens Pregnancy 2001;20:IX–XIV.10.3109/10641950109152635Search in Google Scholar
28. Cetin I, Alvino G. Intrauterine growth restriction: implications for placental metabolism and transport. A review. Placenta 2009;30(Suppl A):S77–82.http://gateway.webofknowledge.com/gateway/Gateway.cgi?GWVersion=2&SrcApp=PARTNER_APP&SrcAuth=LinksAMR&KeyUT=000264245000014&DestLinkType=FullRecord&DestApp=ALL_WOS&UsrCustomerID=b7bc2757938ac7a7a821505f8243d9f310.1016/j.placenta.2008.12.006Search in Google Scholar PubMed
29. Akolekar R, Syngelaki A, Beta J, Kocylowski R, Nicolaides KH. Maternal serum placental protein 13 at 11–13 weeks of gestation in preeclampsia. Prenat Diagn 2009; 29:1103–8.10.1002/pd.2375Search in Google Scholar PubMed
30. Huppertz B, Sammar M, Chefetz I, Neumaier-Wagner P, Bartz C, Meiri H. Longitudinal determination of serum placental protein 13 during development of preeclampsia. Fetal Diagn Ther 2008;24:230–6.http://gateway.webofknowledge.com/gateway/Gateway.cgi?GWVersion=2&SrcApp=PARTNER_APP&SrcAuth=LinksAMR&KeyUT=000259726100014&DestLinkType=FullRecord&DestApp=ALL_WOS&UsrCustomerID=b7bc2757938ac7a7a821505f8243d9f310.1159/000151344Search in Google Scholar PubMed
31. Khalil A, Cowans NJ, Spencer K, Goichman S, Meiri H, Harrington K. First trimester maternal serum placental protein 13 for the prediction of pre-eclampsia in women with a priori high risk. Prenat Diagn 2009; 29:781–9.10.1002/pd.2287Search in Google Scholar PubMed
©2013 by Walter de Gruyter Berlin Boston